Journey Medical announces U.S. FDA acceptance of NDA for DFD-29

Journey Medical Corporation announced that the FDA has accepted the Company’s New Drug Application, NDA, for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act, PDUFA, goal date of November 4, 2024. “We are pleased that the FDA has set a PDUFA date of November 4, 2024 for DFD-29 and we look forward to collaborating with the agency throughout the review process in order to bring this unique treatment option to patients suffering from rosacea,” said Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical. “If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”